Odonate Therapeutics Inc 's ROA from the third quarter of 2021 to the third quarter of 2020 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Odonate Therapeutics Inc 's ROA in the third quarter of 2021?
Odonate Therapeutics Inc recorded a cumulative net loss of $-102 million during 12 months ending in the third quarter of 2021, resulting in a negative return on assets (ROA) of -78.23%.

However, within the Healthcare sector 824 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2021 quarter, so far to 4597, from total ROA ranking in the second quarter of 2021 at 4641.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2021) III. Quarter	(Jun 30 2021) II. Quarter	(Mar 31 2021) I. Quarter	(Dec 31 2020) IV. Quarter	(Sep 30 2020) III. Quarter
Y / Y Total Assets Change	-47 %	-13.19 %	-13.93 %	-12.96 %	-8.32 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-102	-119	-130	-126	-178
Return On Assets (TTM)	-78.23 %	-77.28 %	-82.37 %	-77.33 %	-105.1 %
ODT's Total Ranking	# 4597	# 4641	# 4564	# 5007	# 4548
Total Assets (TTM) in million	103	115	139	164	195
Seq. Total Assets Change	-10.13 %	-17.35 %	-15.18 %	-15.87 %	47.21 %
Seq. Net Income Change	-	-	-	-	-

ODT's 5 Years Annual ROA >> Back to ODT Management Effectiveness >> Compare ODT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 404
Sector	# 825
Overall	# 4470

Return On Assets Statistics
High	Average	Low
30.82 %	-161.07 %	-704.44 %
(Jun 30 2016)		(Dec 31 2017)

Financial Statements
Odonate Therapeutics Inc 's Assets	$ 103 million	ODT's Balance sheet
Odonate Therapeutics Inc 's Income	$ -14 million	Quarterly ODT's Income Statement
ODT's Income by Division		See ODT's Income by Division

Annual Return On Assets	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019	(Dec 31 2018) FY 2018	(Dec 31 2017) FY 2017	(Dec 31 2016) FY 2016
Y / Y Total Assets Change	-13.06 %	32.35 %	43680.84 %	-41.73 %	-57.07 %
Total Assets in million	164	189	143	0	1
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-126	-112	-89	-2	-2
Annual Return On Assets	-76.97 %	-59.22 %	-62.35 %	-694.83 %	-399.09 %

ODT's 5 Years Annual ROA >> Back to ODT Management Effectiveness >> Compare ODT ROA to its Competitors

More Return On Assets Ratios
ODT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ODT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ODT's Competitors
Subscribers only: Roa for Odonate Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for ODT's Customers

You may also want to know
ODT's Roi	ODT's Inventory Turnover Ratio	ODT's Growth Rates	ODT's Dividend Comparisons
	ODT's Profitability Ratios	ODT's Asset Turnover Ratio	ODT's Dividend Growth
ODT's Roe	ODT's Valuation Ratios	ODT's Financial Strength Ratios	ODT's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2021, within Healthcare Sector

ROA

Date modified: 2026-08-29T17:39:09+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.